Three and a half years after the pandemic outbreak, now that WHO has formally declared
that the emergency is over, COVID-19 is still a significant global issue. Here, we focus on …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

Introduction At present, there are some differences in the research results of molnupiravir.
The purpose of this study was to evaluate the efficacy and safety of molnupiravir in the …

Abstract Anti-SARS-CoV-2 monoclonal antibodies are mainstay COVID-19 therapeutics.
Safety, antiviral, and clinical efficacy of bamlanivimab were evaluated in the randomized …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …

Background and aims Coronavirus disease 2019 (COVID-19) imposes a substantial and
ongoing burden on the US healthcare system and society. Molnupiravir is a new oral …

Purpose The aim of our study was to validate a German translation of the post-acute (long)
COVID-19 quality of life (PAC-19QoL) instrument among German patients with long COVID …